This educational activity is directed toward gastroenterologists, primary care clinicians, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with IBD.
Although biologic agents helped usher in a new treatment paradigm for inflammatory bowel disease (IBD), appreciable rates of primary non-response, loss of response, and adverse reactions still require additional treatments. Clinical research has therefore focused on new therapeutic targets and modifications of existing ones to improve the response rates and safety/tolerability profile of IBD medications. Research has resulted in the development of small molecule drugs (SMDs) like selective JAK inhibitors and leukocyte trafficking/migrating inhibitors, and their emergence has created a need for educational activities that help clinicians navigate the ever-expanding clinical armamentarium.
This educational activity is an archive of the live symposium held on May 21, 2022.
Upon completion of this activity, participants should be better able to: